Galectin-3 as a potential biomarker of metabolic disorders and cardiovascular remodeling in patients with hypertension and type 2 diabetes

Bobronnikova, Lesya

doi:10.20517/2574-1209.2016.10

Cited by 12 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, cardiac inflammation and lipotoxicity in obese patients has been attributed to Gal-3 pro-inflammatory properties [ 189 ]. Some studies have even suggested Gal-3 as a potential biomarker of metabolic dysregulation and cardiovascular remodelling in patients with hypertension and T2DM [ 190 ]. Intriguingly, some beneficial effects of Gal-3 have been described.…”

Section: Galectins In Metabolic Disordersmentioning

confidence: 99%

The interplay of galectins-1, -3, and -9 in the immune-inflammatory response underlying cardiovascular and metabolic disease

Mansour

Krautter

Zhi

et al. 2022

Cardiovasc Diabetol

View full text Add to dashboard Cite

Galectins are β-galactoside-binding proteins that bind and crosslink molecules via their sugar moieties, forming signaling and adhesion networks involved in cellular communication, differentiation, migration, and survival. Galectins are expressed ubiquitously across immune cells, and their function varies with their tissue-specific and subcellular location. Particularly galectin-1, -3, and -9 are highly expressed by inflammatory cells and are involved in the modulation of several innate and adaptive immune responses. Modulation in the expression of these proteins accompany major processes in cardiovascular diseases and metabolic disorders, such as atherosclerosis, thrombosis, obesity, and diabetes, making them attractive therapeutic targets. In this review we consider the broad cellular activities ascribed to galectin-1, -3, and -9, highlighting those linked to the progression of different inflammatory driven pathologies in the context of cardiovascular and metabolic disease, to better understand their mechanism of action and provide new insights into the design of novel therapeutic strategies.

show abstract

Section: Galectins In Metabolic Disordersmentioning

confidence: 99%

The interplay of galectins-1, -3, and -9 in the immune-inflammatory response underlying cardiovascular and metabolic disease

Mansour

Krautter

Zhi

et al. 2022

Cardiovasc Diabetol

View full text Add to dashboard Cite

show abstract

“…Estudios clínicos han demostrado que los niveles de Gal-3 en sujetos con HA y DM2 fueron mayores que en el grupo control (p<0,05), esto posiblemente asociado a estrés cardiaco, niveles elevados de angiotensina II (Ang II) y sobrecarga de las cámaras cardiacas por presión elevada (6). Se sugiere que la secreción de Gal-3 está mediada por macrófagos, quienes representan un factor importante en la acumulación y activación de miofibroblastos, siendo estos últimos capaces de inducir fibrosis cardiaca.…”

Section: Participación De Galectina-3 Y Tgf-β1unclassified

Cambios moleculares en la remodelación cardiaca por síndrome metabólico.

López

Martínez

Domínguez³

2020

Rev Cienc Biomed

View full text Add to dashboard Cite

Introducción: el síndrome metabólico (SM) es un conjunto de anormalidades caracterizadas por el aumento de presión arterial, elevación de la glucemia en ayuno, dislipidemias, obesidad y/o diabetes, en donde se encuentran implicadas diversas moléculas que participan en la comunicación intracelular.Objetivo: se describe la función y mecanismo de señalización intracelular que involucra a algunas de las moléculas que llevan a cabo procesos de remodelación cardiaca y son de especial interés como biomarcadores.Métodos: se realizó una selección de literatura que nos describiera la participación de las moléculas en el proceso de remodelación cardiaca como resultado del SM.Conclusiones: el SM y la falla cardiaca se encuentra íntimamente vinculados por la modulación de diversas vías de señalización intracelular que contribuyen a la remodelación cardiaca, generando cambios estructurales modificando la fisiopatología del cardiomiocito.

show abstract

“…Galectin-3 ( Gal-3 ) is a member of the -galactoside-binding family of proteins [5] . It is produced by numerous cells, including vascular, epithelial, interstitial, and immune cells.…”

Section: Introductionmentioning

confidence: 99%

Associations of galectin-3 expression and LGALS-3 (rs4652) gene variant with coronary artery disease risk in diabetics

et al. 2021

View full text Add to dashboard Cite

Background Galectin‑3 protein that is encoded by lectin galactoside-binding soluble-3 (LGALS-3) gene serves as an important genetic factor in type 2 diabetes mellitus (T2DM) and its cardiovascular obstacles in various populations. We aimed to elicit the pro-inflammatory effect of galectin-3 as determined by interleukin-6 (IL-6) serum levels and to explore the relationship between galectin-3 (LGALS-3 rs4652) gene variation and its expression levels with coronary artery disease (CAD) risk among T2DM Egyptian patients. Methods: 112 lean subjects were compared to 100 T2DM without CAD and 84 T2DM with CAD. A tetra-primer amplification refractory mutation system polymerase chain reaction was used to test LGALS-3 (rs4652) and galectin-3 expression was tested with a quantitative real-time polymerase chain reaction. Serum IL-6 was measured using an enzyme-linked immunosorbent assay. Results: We found that the prevalence of LGALS-3 (rs4652) AC genotype and galectin-3 gene expression levels in T2DM with CAD were significantly higher than the additional 2 groups and were correlated positively to IL-6 circulating levels also, the C allele carriers (AC+CC) had significantly higher relative Galectin-3 expression levels compared to the A allele carriers (AA). Conclusion: We concluded that galectin-3 expression levels and LGALS-3 (rs4652) AC genotype were coronary artery disease risk factors in type two diabetics among an Egyptian sample.

show abstract

Galectin-3 as a potential biomarker of metabolic disorders and cardiovascular remodeling in patients with hypertension and type 2 diabetes

Cited by 12 publications

References 14 publications

The interplay of galectins-1, -3, and -9 in the immune-inflammatory response underlying cardiovascular and metabolic disease

The interplay of galectins-1, -3, and -9 in the immune-inflammatory response underlying cardiovascular and metabolic disease

Cambios moleculares en la remodelación cardiaca por síndrome metabólico.

Associations of galectin-3 expression and LGALS-3 (rs4652) gene variant with coronary artery disease risk in diabetics

Contact Info

Product

Resources

About